A phase I/II proof-of-concept study evaluating intramuscular injection of AT-982 in adult subjects with Pompe disease.
Phase of Trial: Phase I/II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs AT 982 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- 06 Feb 2018 According to an Audentes Therapeutics media release, the company plans to file an IND for AT982 in the second quarter of 2018 and plans to initiate a Phase 1/2 clinical study in the fourth quarter of 2018.
- 19 May 2017 New trial record
- 11 May 2017 According to an Audentes Therapeutics media release, preliminary data from this study is anticipated in the second half of 2017.